Immunotherapy has revolutionized cancer treatment by harnessing the power of T cells to attack tumors. But, even when these treatments are successful, scientists often struggle to understand exactly ...

A team of researchers at the Georgia Institute of Technology and Emory University has developed a deep-ultraviolet (UV) ...

The research team engineered CD8+ Jurkat T cells to express SVAR16, a human TCR with intermediate-to-high 2D affinity for the SARS-CoV-2-derived epitope HLAA2:01–YLQ, using lentiviral transduction.

Murad Mamedov, Ph.D., brings expertise in unique, unconventional T cells to advance new cancer immunotherapies.

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Although CAR T-cell therapies have reached significant clinical success in hematological malignancies, their utility in solid tumors remains limited. One of the main challenges is the scarcity of ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...